What is ENCAINIDE used for?

ENCAINIDE is indicated for Ventricular premature beats.

What development phase is ENCAINIDE in?

ENCAINIDE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ENCAINIDE

FDA-approved withdrawn Small molecule Quality 28/100

Encainide is a marketed antiarrhythmic drug primarily indicated for ventricular premature beats, currently holding a position in a competitive landscape dominated by off-patent generics such as propafenone and flecainide. A key strength of Encainide is its patent protection, which extends until 2028, providing a barrier to generic entry and potential revenue stability. The primary risk is the strong presence of established, low-cost generics, which may limit market share and pricing power.

At a glance

Generic name	ENCAINIDE
Drug class	encainide
Target	Sodium channel protein type 5 subunit alpha
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1986

Approved indications

Ventricular premature beats

Common side effects

No common side effects on file.

Drug interactions

ritonavir

Key clinical trials

Cardiac Arrhythmia Suppression Trial (CAST) (PHASE3)
Cardiac Arrhythmia Pilot Study (CAPS) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results